N/A N=1,369 Computer Automation for Diagnosis and Management of Childhood Type 2 Diabetes
Type 2 Diabetes
Primary: Number of Children With Documented Risk Factors for Type 2 Diabetes — 283; 282 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=699 Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)
Diabetes Mellitus, Type II
Primary: Treatment Failure (Loss of Glycemic Control) — 120; 90; 109; 112 participants
Phase 3 N=140 Metformin Therapy for Overweight Adolescents With Type 1 Diabetes
Type 1 Diabetes
Primary: Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c. — 9.0; 8.9; 0.2; 0.2 percentage
Phase 4 N=236 Colesevelam for Children With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Percent Change in Hemoglobin A1c (HbA1c) From Baseline to Month 6 — 0.09; 0.21 percent change — p=0.5494
Phase 3 N=28 Adjunctive Metformin Therapy in Double Diabetes
Diabetes Mellitus
Primary: Baseline Adjusted Hemoglobin A1c Over Time — 9.46; 9.85 percentage of HbA1c — p=0.903
Phase 2 N=24 Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes
Type 2 Diabetes
Primary: Change in Absolute Gluconeogenesis From Baseline to 12 Weeks — 0.018; -0.050 mg/kg LBM/min
N/A N=41 CGM Use in Children With Type 2 Diabetes
Type 2 Diabetes · Hyperglycemia Due to Type 2 Diabetes Mellitus
Primary: Percentage of Time in Range Glucose Control — 49.2; 50.7 percentage of time in target range
Phase 3 N=83 Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes
Children and Adolescent With Type 2 Diabetes
Primary: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) to Week 24 (Controlled Assessment Period) — -0.36; 0.49 percentage (% HbA1c) — p=0.012
N/A N=47 Family Focused Community Program to Prevent Type 2 Diabetes in Peripubertal Youth
Pediatric Obesity
Primary: Change in Percentage Overweight — 1.92; 1.91 change in percent overweight
Phase 3 N=99 A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
Type2 Diabetes · Diabetes Mellitus · Diabetes Mellitus, Type 2
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) — -2.03; -0.23 percentage of HbA1c — p=<0.001
Phase 3 N=122 Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Type 2 Diabetes
Primary: Adjusted Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 28 — 0.11; 0.38 percentage (%HbA1c) — p=0.444
N/A N=30 Use of Continuous Glucose Monitors in Publicly-Insured Youth With Type 2 Diabetes - A Pilot and Feasibility Study
Type 2 Diabetes
Primary: Number of Participants With at Least 75% Wear Time Over 14 Days as a Measure of Sustained CGM Use — 7; 2; 1; 0 Participants
Phase 3 N=6 A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
Diabetes Mellitus, Type 2
Primary: Mean Change in HbA1c From Baseline to Week 16 — -1.0; 0.9 percentage
Phase 1 N=46 Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Cmax: Maximum Observed Plasma Concentration for Alogliptin — 57.82; 101.38; 44.24; 96.74 ng/mL
N/A N=314 Insul-In This Together Program for Adolescents With Type 1 Diabetes and Their Parents
Type 1 Diabetes
Primary: Glucose Levels Percent Time in Target Range Based on Glucose Monitoring — 61.185; 64.542; 62.223; 64.571 percentage of time-in-range — p=0.777
N/A N=10 Pramlintide in Adolescents With Type 1 Diabetes
Type 1 Diabetes
Primary: HbA1c Value After 28 Days — 7.94; 8.72 HbA1c %
Phase 3 N=8 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
Type 2 Diabetes
Primary: Mean Change in HbA1c From Baseline to Week 16 — -0.7; 0.6 percentage
N/A N=33 Diabetes Prevention Program in Youth
Pre Diabetes
Primary: Change From Baseline Hemoglobin A1c — -0.5 A1c percentage points
Phase 2 N=26 Exenatide in Extreme Pediatric Obesity
Obesity
Primary: Percent Change From Baseline in Body Mass Index at 3-months — -2.9; -0.15 percentage of change in BMI
N/A N=40 iStart Smart for Teens for Healthy Weight Management
Overweight · Obese
Primary: Body Mass Index (BMI) — 27.37; 28.35; 26.93; 29.18 kg/m^2 — p=<.001
Phase 1 N=27 Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: AUC0-inf — 1150; 1430; 5060 nmol*h/L
Phase 2 N=12 GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children
Obesity, Morbid
Primary: Change in Body Mass Index (BMI) — -0.9; 0.84 change in kg/m^2
N/A N=48 Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes
Type1diabetes
Primary: Glycemic Control (A1C) — 8.60; 9.35 percentage of glycosylated hemoglobin — p=0.593
N/A N=12 Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)
Diabetes Mellitus, Insulin-Dependent
Primary: Insulin Sensitivity — 8.6; 6.2; 5.8; 4.8 mg/kg/min
Phase 3 N=152 Phase 3 Alogliptin Pediatric Study
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 — -0.011; 0.091 percentage of HbA1c — p==0.782
Phase 3 N=245 Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
Diabetes Mellitus, Type 2
Primary: Dapagliflozin Versus Placebo: Adjusted Mean Change From Baseline in HbA1c at Week 26 — -0.62; 0.41 Percentage HbA1c — p=< 0.001
Phase 3 N=154 A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
Type 2 Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26 — 0.5; -0.7 percentage of HbA1C — p=<0.001
Phase 3 N=175 Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c) (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ — NA; 0.33; -0.17; -0.49 Percent change — p=0.2935
Phase 2 N=100 Metformin to Treat Obesity in Children With Insulin Resistance
Hyperinsulinemia · Obesity
Primary: Changes in Body Weight as Determined by Body Mass Index-standard Deviation Score (BMI-SDS). — -0.11; -0.07 Units on a scale
N/A N=302 Communication and Coping for Mothers of Adolescents With Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Glycemic Control (A1C) — 8.4; 8.5 Percentage of glycated hemoglobin